Vistagen announces positive results from phase 2a pilot study of ph15 for improvement of psychomotor impairment caused by mental fatigue

South san francisco, calif.--(business wire)---- $vtgn #mentalhealth--vistagen (nasdaq: vtgn), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced positive results from a phase 2a pilot study of ph15, an investigational pherine nasal spray, for improvement of psychomotor impairment caused by mental fatigue. ph15 demonstrated a statistically significant improvement in reaction time compared to placebo.
VTGN Ratings Summary
VTGN Quant Ranking